REG-Bioventix Plc: Trading Update and Notice of Results <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

22/08/2016 09:29

Bioventix plc

(“Bioventix” or the “Company”)

Trading Update and Notice of Results

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for application in
clinical diagnostics, announces a trading update.

The Board is pleased to report that revenues for the financial year ended 30
June 2016 are expected to be in excess of £5.3M (2015: £4.33M). A strong
performance during the financial year has been supplemented by a positive
exchange rate effect. Since the cost base of the Company follows the same
trajectory as in previous years, both revenues and profits before tax are
expected to be  ahead of market expectations for the year ended 30 June 2016.

The Board is encouraged by the recent development activities of our partner,
Siemens Healthcare Diagnostics. A Bioventix-created antibody is being used in
a Siemens troponin product that is under development, as mentioned in a
scientific presentation at the August 2016 American Association of Clinical
Chemistry. Troponin remains an important product for Bioventix’s future
performance, as we expect to commence significant sales during the financial
year ending 30 June 2018, which will offset revenues from other products which
are expected to reduce during this period.

Notice of Results

The audited accounts for the year ended 30 June 2016 are due to be released on
Monday 17 October 2016.

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

For further information please contact:

 Bioventix plc Peter Harrison                         Chief Executive Officer              Tel: 01252 728 001  
                                                                                                               
 finnCap Ltd Geoff Nash/Simon Hicks Stephen Norcross  Corporate Finance Corporate Broking  Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2016 PR Newswire Association,LLC. All Rights Reserved